Company

GeneScience Pharmaceuticals' 6‑Month Long‑Acting Leuprolide Mesylate Injection Approved in China – First Half‑Year Dosing GnRHa for Prostate Cancer ADT
CancerGeneScience Pharmaceutical

GeneScience Pharmaceuticals’ 6‑Month Long‑Acting Leuprolide Mesylate Injection Approved in China – First Half‑Year Dosing GnRHa for Prostate Cancer ADT

GeneScience Pharmaceuticals Co., Ltd. announced that its long-acting anticancer drug, leuprolide mesylate injection (6M), has been approved for marketing by China's National Medical Products Administration (NMPA) for the treatment of…

Daiichi Sankyo's DATROWAY Approved in China for New Indication – TROP2 ADC Extends Survival in Unresectable or Metastatic Triple‑Negative Breast Cancer

Daiichi Sankyo’s DATROWAY Approved in China for New Indication – TROP2 ADC Extends Survival in Unresectable or Metastatic Triple‑Negative Breast Cancer

Sun‑Novo and Vanguard Pharmaceutical Sign Co‑Development Agreement for ABA001 – GalNAc‑Conjugated siRNA Targeting Angiotensinogen in Hypertension

Sun‑Novo and Vanguard Pharmaceutical Sign Co‑Development Agreement for ABA001 – GalNAc‑Conjugated siRNA Targeting Angiotensinogen in Hypertension

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
DiabetesEli Lilly

Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement

BiosimilarsCancer

Henlius Biotech’s Perjeta Biosimilar HLX11 (Poherdy) Secures NMPA Approval for HER2-Positive Breast Cancer in China

True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations
CancerIPO

True Health Medical Files Hong Kong IPO for Percutaneous Surgery Robot Portfolio with Multiple China-First Innovations

Clinical trial approval / initiationKanghua Biological Products

Chengdu Kanghua Initiates Phase II Trial for RSV mRNA Vaccine Through NanoRibo Acquisition in China’s Untapped Market

Show More